

PILOT PHASE

n=5 patients affected by PSP

PRE-TREATMENT ASSESSMENT:
Motor, neuropsychological and neuroimaging assessments

BONE MARROW COLLECTION

MESENCHYMAL CELL PRODUCTION

**n=5 patients
(arteriography + MSC)**

8 weeks FOLLOW-UP ASSESSMENT:
Cell administration safety + motor, neuropsychological and neuroimaging assessments

12 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments

18 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments

(A)**RANDOMIZED STUDY**

n=20 patients affected by PSP

PRE-TREATMENT ASSESSMENT:
Motor, neuropsychological and neuroimaging assessments

BONE MARROW COLLECTION

MESENCHYMAL CELL PRODUCTION

**n=10 patients
1st intervention
(arteriography + MSC)**

**n=10 patients
1st intervention
(sham procedure)**

6 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments

**n=10 patients
2nd intervention
(sham procedure)**

**n=10 patients
2nd intervention
(arteriography + MSC)**

12 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments.

18 MONTH FOLLOW-UP ASSESSMENT:
Safety. Motor, neuropsychological and neuroimaging assessments

(B)